Edition:
United States

People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,912.00GBp
22 Sep 2017
Change (% chg)

143.50 (+3.01%)
Prev Close
4,768.50
Open
4,813.50
Day's High
4,954.50
Day's Low
4,772.50
Volume
4,223,049
Avg. Vol
2,570,747
52-wk High
5,585.07
52-wk Low
3,996.00

Soriot, Pascal 

Mr. Pascal Soriot is Executive Director and Chief Executive Officer of AstraZeneca PLC. Mr. Pascal was appointed as a Director and CEO in October 2012. From 2010 to September 2012, he served as Chief Operating Officer of Roche AG’s pharmaceuticals division. Prior to that, he was CEO of Genentech, a biologics business, and led its successful merger with Roche. He joined the pharmaceutical industry in 1986 and has worked in senior management roles throughout the world in a number of major companies. He brings to AstraZeneca a significant breadth of experience in both established and emerging markets, strength of strategic thinking, a successful track record of managing change and putting strategy into operation, and the ability to lead a diverse organisation, having lived in Australia, Japan, the US and Europe. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.

Basic Compensation

Total Annual Compensation, GBP 2,378,000
Restricted Stock Awards, GBP --
Long-Term Incentive Plans, GBP 10,533,000
All Other, GBP 478,000
Fiscal Year Total, GBP 13,389,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leif Johansson

611,000

Pascal Soriot

13,389,000

Marc Dunoyer

4,450,000

Fiona Cicconi

--

Sean Bohen

--

Pam Cheng

--
As Of  30 Dec 2016